BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
2 Golic M, Luft FC, Dechend R. Tumor Necrosis Factor-α, Uterine Natural Killer Cells, and Pregnancy. Hypertension 2016;68:1108-9. [DOI: 10.1161/hypertensionaha.116.08028] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Epelboym Y, Shyn PB, Chick JFB, Hamilton MJ, O'connor SD, Silverman SG, Kim CK. Crohn Disease: FDG PET/CT Before and After Initial Dose of Anti–Tumor Necrosis Factor Therapy to Predict Long-term Response. Clin Nucl Med 2017;42:837-41. [DOI: 10.1097/rlu.0000000000001844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol 2020;32:371-9. [PMID: 32412995 DOI: 10.1097/BOR.0000000000000713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
5 Chupin A, Perduca V, Meyer A, Bellanger C, Carbonnel F, Dong C. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1289-97. [PMID: 32840893 DOI: 10.1111/apt.16050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Shwaartz C, Fields AC, Sobrero M, Cohen BD, Divino CM. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience. J Gastrointest Surg 2016;20:1636-42. [DOI: 10.1007/s11605-016-3194-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Papamichael K, Cheifetz AS, Irving PM. New role for azathioprine in case of switching anti-TNFs in IBD. Gut 2020;69:1165-7. [PMID: 32075889 DOI: 10.1136/gutjnl-2020-320677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Garcia PG, Chebli LA, da Rocha Ribeiro TC, Gaburri PD, de Lima Pace FH, Barbosa KVBD, Costa LA, de Almeida Cruz W, de Assis IC, Moraes BRM, Zanini A, Chebli JMF. Impact of superimposed Clostridium difficile infection in Crohn’s or ulcerative colitis flares in the outpatient setting. Int J Colorectal Dis 2018;33:1285-94. [DOI: 10.1007/s00384-018-3105-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cheng J, Shen H, Chowdhury R, Abdi T, Selaru F, Chen JDZ. Potential of Electrical Neuromodulation for Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2020;26:1119-30. [DOI: 10.1093/ibd/izz289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
10 Jairath V, Mcdonald JW, Feagan BG. Ulcerative Colitis. In: Feagan BG, Kahrilas PJ, Jalan R, Mcdonald JWD, editors. Evidence-based Gastroenterology and Hepatology 4e. Chichester: John Wiley & Sons, Ltd; 2019. pp. 173-86. [DOI: 10.1002/9781119211419.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Louis E. Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:302. [PMID: 31970158 DOI: 10.3389/fmed.2019.00302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
13 Detrez I, Van Stappen T, Martín Arranz MD, Papamichael K, Gils A. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Ther Drug Monit 2017;39:344-9. [PMID: 28328760 DOI: 10.1097/FTD.0000000000000394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
14 Armuzzi A, Ardizzone S, Biancone L, Castiglione F, Danese S, Gionchetti P, Orlando A, Rizzello F, Scribano ML, Vecchi M, Daperno M. Ustekinumab in the management of Crohn’s disease: Expert opinion. Digestive and Liver Disease 2018;50:653-60. [DOI: 10.1016/j.dld.2018.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
16 Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study. J Crohns Colitis 2017;11:297-304. [PMID: 27660339 DOI: 10.1093/ecco-jcc/jjw166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
17 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
18 Mengi G, Göğüş F. A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis. Arch Rheumatol 2017;32:67-70. [PMID: 30375550 DOI: 10.5606/ArchRheumatol.2017.6055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Nahon S, Lahmek P, Macaigne G, Lesgourgues B, Paupard T. Crohn's disease treatment practices in France in1999-2013: A prospective survey in non-academic hospitals. Clin Res Hepatol Gastroenterol 2018;42:470-7. [PMID: 29625924 DOI: 10.1016/j.clinre.2018.03.004] [Reference Citation Analysis]
20 Razvi M, Lazarev M. Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 2017;18:263-72. [DOI: 10.1080/14712598.2018.1410131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]